American Journal of Psychiatry

Article	Citations
Treating Pathologies of the Will	235
Evaluating Associations Between Cannabis and Heroin Use	188
Broadening the Parameters of Clinical High Risk for Psychosis	162
2024 Annual Meeting: Presidential Address	153
From Scanner to Bedside: Building Bridges in Translational Psychiatric Neuroimaging	152
From Prediction to Action: Moving Beyond Machine Learning to Implementing Evidence-Based Perinatal Mental Health Care	140
Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?	137
Updates and Advances in the Treatment of Substance Use Disorders, Depression, and Borderline Personality Disorder	128
Can Neuromelanin-Sensitive MRI Provide Insight Into the Dopaminergic Pathways Contributing to Substance Use?	120
Mental Health Disparities Research: An Introduction to New Directions	118
Reconsidering the Interpretive Basis of Neural Efficiency as a Biomarker in Pediatric Anxiety: Response to Ai and Colleagues	111
Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders	107
Depression, Inflammation, and Postpartum Psychosis	103
Neuroplasticity, Antipsychotic Efficacy, Schizophrenia Risk Reduction With Doxycycline Exposure, and Cannabis and Alcohol Use Interactions	99
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now	98
Cannabis and Brain Health: What Is Next for Developmental Cohort Studies?	97
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosi	93
Future of Sensorimotor and Psychomotor Dysfunction in Mental Disorders: Emerging Tools, Methodological Challenges, and the Road Ahead	90
A New Agenda for Optimizing Investments in Community Mental Health and Reducing Disparities	89
Neural Signatures of Pain Modulation in Short-Term and Long-Term Mindfulness Training: A Randomized Active-Control Trial	79
Correcting Overestimations in Self-Harm Visit Data	77
Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.	76
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression	75
Correction to Poirot et al.	75
Corrigendum to Morley et al.	73

Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression	72
Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population	72
Primary Prevention of PTSD Symptoms in Combat-Deploying Soldiers Using Attention Bias Modification: A Randomized Controlled Trial	71
2024 Annual Meeting: CEO and Medical Director’s Address	68
Older Adults are at Heightened Risk of the Effects of Cannabis Use: Response to Walaszek	66
The First Large GWAS Meta-Analysis for Postpartum Depression	65
12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use	64
Highlights From the Residents’ Journal: September 2024	63
Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder	62
Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden	62
Familial Risk of Postpartum Psychosis	61
Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability	60
Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents	58
New Insights Into Psychotic Disorders	58
Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia	57
Reduced Threat-Related Neural Efficiency: A Possible Biomarker for Pediatric Anxiety Disorders	56
Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	55
Suicide and the Menstrual Cycle	53
Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder	52
Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh	52
Genetic and Environmental Contribution to the Co-Occurrence of Endocrine-Metabolic Disorders and Depression: A Nationwide Swedish Study of Siblings	52
Rebecca W. Brendel, M.D., J.D., 149th President, 2022–2023	52
Proof-of-Principle Study on ECT Illustrates Challenges and Possible Merits of Using Polygenic Risk Scores to Predict Treatment Response in Psychiatry	52
Toward Inclusive, Evidence-Based rTMS Care for Patients With Co-Occurring Substance Use Disorders: Response to Steele et al.	50
Associations Between a Primary Care-Delivered Alcohol-Related Brief Intervention and Subsequent Opioid-Related Outcomes	49
Sexual Identity Continuity and Change in a U.S. National Probability Sample of Sexual Minority Adults: Associations With Mental Health and Problematic Substance Use	48
Alcohol and the Etiology of Depression	47
Sustained Efficacy of Stanford Neuromodulation Therapy (SNT) in Open-Label Repeated Treatment	47
From Crisis to Action: Psychiatry’s Ethical Imperative to Defend Transgender People’s Rights, Dignity, and Access to Care	46
Shared and Specific Neural Correlates of Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder: A Meta-Analysis of 243 Task-Based Functional MRI Studies	45
Biosocial Implications of Indigenous Trauma	45
Risk of Incident Psychosis and Mania With Prescription Amphetamines	44
Beyond Symptom Thresholds: Toward a Clinically and Culturally Inclusive Definition of Relapse in Schizophrenia	43
Ketamine for Depression, but at What Cost? A Review of Ketamine’s Neurotoxic Effects From Preclinical and Human Studies	43
Predictive Value of Acute Neuroplastic Response to rTMS in Treatment Outcome in Depression: A Concurrent TMS-fMRI Trial	42
Resting-State Functional Connectivity of the Amygdala and Hippocampus in PTSD: Results From the PGC-ENIGMA PTSD Working Group	42
Smoking Cessation Treatment: Still Seeking a New Approach?	42
Suicide in Black Females	41
The Safety of Pimavanserin for Parkinson’s Disease and Efforts to Reduce Antipsychotics for People With Dementia	41
Psilocybin: From Psychiatric Pariah to Perceived Panacea	40
Diagnosing Prescription Opioid Use Disorder in Patients Using Prescribed Opioids for Chronic Pain	39
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary	39
Neural Correlates of Stress and Alcohol Cue-Induced Alcohol Craving and of Future Heavy Drinking: Evidence of Sex Differences	39
What Do Four Decades of Research Tell Us About the Association Between Childhood Adversity and Psychosis: An Updated and Extended Multi-Level Meta-Analysis	39
Treatment Response Prediction in Major Depressive Disorder Using Multimodal MRI and Clinical Data: Secondary Analysis of a Randomized Clinical Trial	38
Predicting Acute Changes in Suicidal Ideation and Planning: A Longitudinal Study of Symptom Mediators and the Role of the Menstrual Cycle in Female Psychiatric Outpatients With Suicidality	38
Reduction in Trauma-Related Symptoms After Anesthetic-Induced Intra-Operative Dreaming	38
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression	38
Double-Blind, Sham-Controlled Randomized Trial Testing the Efficacy of fMRI Neurofeedback on Clinical and Cognitive Measures in Children With ADHD	36
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders	36

Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder	36
Can Smartphone-Based Support Apps Add Value to the Treatment of Opioid Use Disorder?	35
Correction to Baum et al.	35
Drug Cues Trigger Corticolimbic Hyperreactivity in Heroin Users	35
The Association of Childhood Maltreatment and Mental Health Problems: Partly Causal and Partly Due to Other Factors	35
Harnessing the Power of Population Cohorts to Study the Relationship Between Endocrine-Metabolic Disorders and Depression	34
Keeping Track and Providing Tools for Future Crisis Management: Suicide Attempt and Self-Harm Presentations at Emergency Departments	34
Beneath the Phenotypic Surface: Pleiotropy Shapes the Co-Occurrence of Alcohol Use Disorder and Psychopathology	33
Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary	33
A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability	33
Differences in Social Determinants of Health Underlie Racial/Ethnic Disparities in Psychological Health and Well-Being: Study of 11,143 Older Adults	32
When Will There Be Good News?	32
Mortality Among Parkinson’s Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries	32
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial	32
Co-Use of Alcohol and Cannabis: How Are They Related?	31
Racial and Ethnic Biases and Psychiatric Misdiagnoses: Toward More Equitable Diagnosis and Treatment	30
Setting the Record Straight on Long-Term Use, Dose Escalation, and Potential Misuse of Prescription Benzodiazepines	30
Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments	30
Innovative Directions to Advance Mental Health Disparities Research	30
Correction	29
Toward Precision Noninvasive Brain Stimulation	29
Psychiatric Diagnoses in Parents and Psychiatric, Behavioral, and Psychosocial Outcomes in Their Offspring: A Swedish Population-Based Register Study	29
Evaluating the Evidence for Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma	29
The Amygdala and Depression: A Sober Reconsideration	29
Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?	28
2024 Articles of Import and Impact	28
Highlights From the Residents’ Journal: December 2024	28
Understanding the Effects of Combined Lisdexamfetamine and Cognitive Behavior Therapy for Adults With Binge Eating Disorder	28
The Future of DSM : A Strategic Vision for Incorporating Socioeconomic, Cultural, and Environmental Determinants and Intersectionality	27
Adolescent Suicidality and Depression, Premenstrual Dysphoric Disorder, and Safety Issues Related to Ketamine and Esketamine Treatment	27
Progress and Challenges in GxE Research on Depression	26
Personalizing Brain Stimulation for Psychiatric Disorders: From Circuits to Closed-Loop Control	26
Converging Evidence for Frontopolar Cortex as a Target for Neuromodulation in Addiction Treatment	26
Guilt by Association: Inflammation and Shared Genetic Risk Between Stress-Related and Immune Disorders	26
Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy	26
Drugs and Addiction Science: NIDA Celebrates 50 Years of Research and Looks to the Future	26
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them	25
Meta-Analyses of Genome-Wide Association Studies for Postpartum Depression	25
Current and Future Approaches to Pediatric Anxiety Disorder Treatment	25
Associations Between General and Specific Mental Health Conditions in Young Adulthood and Cardiometabolic Complications in Middle Adulthood: A 40-Year Longitudinal Familial Coaggregation Study of 672,	25
Longitudinal Trajectory of the Link Between Ventral Striatum and Depression in Adolescence	25
Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia? Response to Tandon	24
Vaccines as Immunotherapies for Substance Use Disorders	24
Technology and Mental Health: State of the Art for Assessment and Treatment	24
Can Two 90-Minute Workshops Reduce Risk of Substance Use Disorder for Vulnerable Seventh Graders? Results and Scalability From the Co-Venture Trial	24
Functional Connectivity Mapping for rTMS Target Selection in Depression	24
Antidepressants and Bipolar Disorder: The Plot Thickens	23
Perinatal Mental Health: Advances and Opportunities	23
Recapitulation of Perturbed Striatal Gene Expression Dynamics of Donors’ Brains With Ventral Forebrain Organoids Derived From the Same Individuals With Schizophrenia	23
The Evolving ADHD Phenotype in the Externalizing Context	22
Psychotropic Drug–Related Weight Gain and Its Treatment	22
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research	22
Understanding the Efficacy and Mechanism of Action of a Dextromethorphan-Bupropion Combination: Where Does It Fit in the NMDA Versus mu-Opioid Story?	22
Late-Life Depression, Antidepressant Treatment, and Cognition: The Short Haul and the Long Haul	22
Highlights From the Residents’ Journal: September 2023	22
Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction	22
Prevalence and Penetrance of Rare Pathogenic Variants in Neurodevelopmental Psychiatric Genes in a Health Care System Population	22
Varenicline as a First-Line Treatment for Individuals With Current Major Depressive Disorder Who Smoke Cigarettes	22
Neglect of Adverse Effects in Treatment Guidelines for Depression	21
Neuropsychiatric Symptoms of Subacute and Chronic Long COVID	21
Clozapine’s High Incidence of Ileus and Pneumonia Demand Better Clinical Strategies—How Do We Get There?	21
Improved Response Inhibition Through Cognition-Guided EEG Neurofeedback in Men With Methamphetamine Use Disorder	21
Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia	21
Polygenic Risk Scores and Genetics in Psychiatry	21
Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment	21
Focusing on Substance Use Disorders, Opioids, and Craving	21
Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial	21
Intermittent Theta Burst Stimulation With Adjunctive D-Cycloserine for Obsessive-Compulsive Disorder: A Randomized Clinical Trial	21
The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders	20
An Insula-Enriched Regulator of Retinoic Acid Marks a New Intersection in the Neural Circuitry of Mouse Social Behavior	20
Pathogenic Variants and Ascertainment: Neuropsychiatric Disease Risk in a Health System Cohort	20
Inner-Directed Therapy in MDMA-Assisted Psychotherapy	20
Don’t Throw the Baby Out With the Bathwater: A Need for Nuanced Practice and Additional Research on Telehealth Management of ADHD	20
Is It Time for a Universal Outcome Measure to Deliver on the Promises of Interventional Psychiatry?	20
Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA Study	19
Highlights From the Residents’ Journal: June 2025	19
Reports to the Membership	19
Beyond the Landmarks: Where to Next With Biomarkers of Autism?	19
MORE Is Less Pain and Less Opioid Misuse: A Mindful Remedy	19
Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder	19

Affective Disorders, Pharmacogenomics, and Psychiatric Illness-Related Cardiometabolic Problems	19
Disclosure of Editors’ Financial Relationships	19
Intergenerational Effects of the Fast Track Intervention on Next-Generation Child Outcomes: A Preregistered Randomized Clinical Trial	18
Xanomeline-Trospium Treatment of Cognitive Impairments of Schizophrenia: Hope for Some, or Hope for All?	18
Psychosis Risk With Prescription Amphetamine	18
MDMA and MDMA-Assisted Therapy	18
Intravenous Brexanolone for the Treatment of Posttraumatic Stress Disorder: A Case Report	18
Association Between Polygenic Risk Scores and Outcome of ECT	18
Prospective Associations Between Structural Brain Development and Onset of Depressive Disorder During Adolescence and Emerging Adulthood	17
Treating Depression With Repetitive Transcranial Magnetic Stimulation: A Clinician’s Guide	17
The Intergenerational Impact of Structural Racism and Cumulative Trauma on Depression	17
Real-World Evidence on Clinical Outcomes of Commonly Used Antidepressants in Older Adults Initiating Antidepressants for Depression: A Nationwide Cohort Study in Denmark	17
An Honest Reckoning With the Amygdala and Mental Illness	17
Adolescent Substance Use and Suicidal Behavior, Internet Overuse, and Shared Genetics Between Problematic Alcohol Use and Other Psychiatric Comorbidities	16
Disclosure of Editors’ Financial Relationships	16
Drug Overdose Prevention: An Exercise in Optimism	16
Seeking New Solutions Addressing Structural Racism, Childhood Trauma, Suicidal Behaviors Across Sexual Orientations, and Postpartum Depression	16
Mechanism-Focused Randomized Controlled Trials in Youths: Another Step Uphill	16
What is the Link Between Substance-Induced Psychosis and Primary Psychotic Disorders?	15
Can Cognitive-Behavioral Therapy Normalize Neural Function in Youths With Pediatric Anxiety Disorders? A Developmental Neuroscience Perspective	15
The Importance and Limitations of Null Findings	15
Prevalence of Suicidal Ideation and Suicide Attempts by Race and Gender in Three Large U.S. Adolescent Cohorts	15
Real-Time Assessment of Alcohol Reward, Stimulation, and Negative Affect in Individuals With and Without Alcohol Use Disorder and Depressive Disorders	15
20 Years of Aberrant Salience in Psychosis: What Have We Learned?	15
Inequalities in the Incidence of Psychotic Disorders Among Racial and Ethnic Groups	15